Study of NXT007 for severe or moderate hemophilia A
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This trial tests a new medicine called NXT007 to see if it is safe and effective for people with severe or moderate hemophilia A, including those with inhibitors. It may help reduce bleeding episodes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have severe or moderate hemophilia A (with or without inhibitors).
- You are not currently receiving immune tolerance induction therapy and have not had it in the last 5 years if you previously completed it.
- You have no history of blood clots, heart disease, or stroke.
- You have not had gene therapy or any other investigational drug recently.
- Your blood counts, liver, and kidney function are within acceptable ranges.
- You are willing to track your bleeding episodes and follow study procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called NXT007 for people with hemophilia A. It compares NXT007 to standard factor VIII treatment to see if it works better at preventing bleeding episodes.
This trial tests if a new medicine, NXT007, is better than emicizumab at preventing bleeding episodes in people with hemophilia A. It may be an option for those with or without inhibitors who are willing to switch to a preventive treatment.
This early-phase trial tests a new gene therapy called NGGT003 for men with severe hemophilia A. It aims to see if the treatment is safe and can help reduce bleeding episodes.
This trial tests a new gene therapy called SPK-8011QQ for adults with severe or moderately severe hemophilia A. The goal is to see if a single infusion can help your body produce its own factor VIII, reducing or stopping the need for regular factor VIII injections.
This early-phase study tests an FVIII gene therapy to help your body make more of the missing clotting factor in hemophilia A. It’s aimed at adults with severe low FVIII levels who have already used FVIII replacement products for a long time and have not developed an immune blocker (an inhibitor).
This trial tests a new injection called GS1191-0445 for people with hemophilia A. It aims to see if it is safe and works well to prevent or treat bleeding episodes.
Hear when a new Hemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.